What is Profluent Bio?
Headquartered in Berkeley, CA, and founded in 2022, Profluent Bio is at the forefront of protein design, leveraging deep generative AI models. The company's core mission is to engineer and validate functional proteins that can transform the biomedical field. By developing sophisticated AI-driven platforms, Profluent Bio is poised to address complex biological challenges and unlock new therapeutic and diagnostic possibilities. The company's innovative approach places it as a key player in the burgeoning field of AI in life sciences.
How much funding has Profluent Bio raised?
Profluent Bio has raised a total of $141M across 2 funding rounds:
Other Financing Round
$35M
Other Financing Round
$106M
Other Financing Round (2024): $35M with participation from Insight Partners, Spark Capital, and Air Street Capital
Other Financing Round (2025): $106M led by Bezos Expeditions, Spark Capital, Altimeter Capital, and Insight Partners
Key Investors in Profluent Bio
Bezos Expeditions
Bezos Expeditions is an investment firm founded by Jeff Bezos that focuses on a diverse range of sectors including technology, healthcare, and space exploration. The firm is known for its strategic investments in innovative companies such as Airbnb, Uber, and Twitter.
Spark Capital
Spark Capital, investors in products we love by creators we admire, including Affirm, Carta, Coinbase, Cruise, Discord, Oculus, Plaid, Postmates, Slack, Twitter, and Wayfair. We know there are no playbooks or formulas for success and are here to help founders win their own way.
Altimeter Capital
Altimeter Capital is an investment firm that partners with technology companies from early growth through public markets. It manages concentrated, long term portfolios and works closely with founders and teams to support product, strategy and durable value creation.
What's next for Profluent Bio?
With substantial enterprise-level backing, Profluent Bio is strategically positioned for significant growth and expansion. The recent major strategic investment will likely fuel further research and development, enabling the company to scale its AI capabilities and broaden its protein design pipeline. This capital infusion is expected to accelerate the translation of its innovative protein designs into tangible solutions for the healthcare industry, potentially leading to new drug discoveries and advanced biotechnological tools. Profluent Bio's trajectory suggests a strong focus on market penetration and establishing leadership in AI-driven protein engineering.
See full Profluent Bio company page
